
According to the company, Shreehas Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Indian benchmark indices are likely to open higher on F&O expiry amid firm global cues. SGX Nifty hinted at a…
The strategic alliance with Serum Institute Life Sciences (SILS) for vaccines is on track for closure by Q3FY22, the company…
John Shaw, who had served the Bengaluru-headquartered biopharmaceutical company as the Vice-Chairman and Non-Executive Director for over 22 years, passed…
To those who have seen the couple from outside, John Shaw seemed a pillar of support for Kiran Mazumdar in…
Reportedly, Biocon Biologics became the first company from India to commercialize a biosimilar in Japan, after its Insulin Glargine was…
Shaw also emphasised on the importance of cleanliness and how it is a factor that will determine our country’s future…
The bribe was allegedly for favourably recommending the file of Insulin Aspart Injection to the Subject Expert Committee (SEC) meeting…
The appellant was also penalised for a sum of Rs 2 lakh.
In the corresponding quarter last year, the company posted a net profit of Rs 84.4 crore.
Roshni Nadar Malhotra, the chairperson of HCL Technologies, has retained the tag of the richest woman in India for the…
According to the company’s press statement, the facility, spread across 340,000 square feet, will enhance the capabilities to manufacture drug…
Indian equity markets are likely to extend losses on Thursday as SGX Nifty signalled at a gap-down open for benchmark…
After a dismal start, benchmark indices recovered most of their losses on Wednesday as metals and some energy counters gathered…
The vaccines alliance with Serum and our continued investment in R&D, adding products to our portfolio, opens up new growth…
Inpremzia has been developed by Celerity Pharmaceuticals LLC using Biocon Biologics’ biosimilar insulin drug substance, Biocon Ltd said in a…
Mr John Shaw, who is a Glasgow University graduate, along with his wife Ms Kiran Mazumdar- Shaw had gifted $7.5…
Post the closure of the Viatris’ deal, Biocon Biologics will realise the full revenue and profits from its products, which…
The two day FE Pharma Summit 2022 is also an attempt to leverage the ability of the Indian pharma stakeholders…
Valuation of Viatris’ biz is expensive; FY23/24e EPS up 3.4/15% with TP at Rs 385; ‘Neutral’ retained given limited upside
Biocon’s recent acquisition of Viatris’ biosimilar assets offers significant long-term growth opportunities. However, a substantially higher debt to fund the…
Biocon shares posted their biggest single-day fall since August 2015.
Loading…
Something went wrong. Please refresh the page and/or try again.